FigureAsia 35 Under 35 · Healthcare
Anirudh Joshi
Age 29 · Computational pathology and cancer care · Palo Alto, United States
Founder and study author behind multicentre bladder-cancer models that reached an FDA Breakthrough Device designation in May 2026.
- Approximate age at 31 December 2025
- 29
- Field
- Healthcare
- Country or region
- Palo Alto, United States
- FigureAsia U35 Assessment
- 84.8 / 100
Profile
Career and documented record
Anirudh Joshi has built computational pathology around a question more demanding than image classification: can a routine tumour slide help predict which course of care is likely to work? During 2025 and 2026, the company's Vesta bladder-cancer models were assessed in international multicentre research and in a six-centre US real-world cohort. Joshi appears as a named author on the 2026 real-world study, giving his role a scientific record in addition to his accountability as cofounder and chief executive.
In May 2026, the company announced that one Vesta risk-stratification device received an FDA Breakthrough Device designation. That designation can facilitate development and review for technologies addressing serious conditions; it is not clearance, approval or proof of clinical benefit. The difference is central to FigureAsia's wording.
Joshi's contribution lies in the movement from model development toward multicentre evidence and a formal regulatory-development pathway. The studies include company-affiliated authors and potential conflicts, so independent replication and prospective utility remain important. Even with those limits, the work has brought a young Indian-American founder into one of the hardest parts of medical AI: linking morphology to decisions that affect cancer treatment.
FigureAsia selection
Why Anirudh Joshi is on the list
FigureAsia selected Joshi for the combination of founder agency, multicentre study participation and a meaningful — but accurately bounded — regulatory milestone. Many pathology models never leave retrospective demonstrations. His 2025–2026 record shows a deliberate route toward real-world evaluation and regulator engagement. The score is moderated because designation is not market authorization and because clinical utility still needs prospective, independent evidence.
Verified work
The 2025–26 record
Principal milestone
Six-centre US real-world study
Evidence record
International multicentre evaluation inside the assessment window
Scale or implementation
Breakthrough Device designation announced 15 May 2026
Field context
The work in its field
Within computational pathology and cancer care, the relevant test is whether a result can survive scrutiny of maturity, attribution, validity and practical fit. That distinction matters: completed evidence is not projected benefit, and individual responsibility is not interchangeable with the wider team’s achievement.
FigureAsia U35 Assessment
Assessment breakdown
84.8out of 100
Substantive 2025–2026 contribution
18 / 20
The score reflects completed 2025–26 work in computational pathology and cancer care, assessed at the documented maturity of multicentre validation and regulatory development.
Verified impact
12 / 15
Impact credit is limited to the measured study, regulatory, implementation or operating record stated in the profile; unsupported patient benefit is excluded.
Originality and distinction
8 / 10
The work creates or materially advances a distinctive capability within computational pathology and cancer care rather than relying on title or institutional association.
Field and industry influence
8 / 10
The assessment recognises demonstrated effects on research, product development, care delivery or professional practice, with publicity alone carrying no weight.
Individual agency
10 / 10
Named authorship and the documented role of Cofounder and Chief Executive Officer establish individual responsibility while preserving credit for collaborators.
Durability and trajectory
4 / 5
The cited work forms part of a continuing programme, platform or research trajectory rather than a single uncompleted announcement.
Asian significance and global relevance
4 / 5
The Asian connection is material to the person's identity, operating base or populations served: Indian-American computational-health founder.
Clinical and scientific validity
6.3 / 7
Clinical and scientific validity is calibrated to multicentre validation and regulatory development, with the profile retaining the evidence boundary attached to the result.
Safety, quality and responsible governance
5.6 / 7
Safety and governance credit reflects accurate regulatory language, study limitations, data stewardship and the refusal to turn early evidence into clinical certainty.
Translation and care-pathway fit
5.4 / 6
The work is scored for its demonstrated fit with a laboratory, regulatory, clinical, operational or public-health pathway, not for projected future adoption.
Access, equity and resource stewardship
3.5 / 5
Access credit reflects documented reach, capacity, affordability or inclusion while distinguishing service volume from proven clinical outcome.